[Clinical progress of neutralizing antibodies against SARS-CoV-2].
Sheng Wu Gong Cheng Xue Bao
; 38(6): 2061-2068, 2022 Jun 25.
Article
in Chinese
| MEDLINE | ID: covidwho-1912221
ABSTRACT
Since the palivizumab for respiratory syncytial virus was approved in 1998, therapeutic antibodies against infectious diseases have been widely used in clinical treatment. Since the outbreak of COVID-19, plenty of neutralizing antibodies were developed and transferred into clinical trials, holding enormous promise for the treatment of COVID-19 under the context of emergency use authorization. This review summarizes the clinical progress of these drugs, in order to provide a reference for the research and development of neutralizing antibody drugs for the future.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Sheng Wu Gong Cheng Xue Bao
Journal subject:
Biotechnology
Year:
2022
Document Type:
Article
Affiliation country:
J.cjb.220118
Similar
MEDLINE
...
LILACS
LIS